40 results about "Esophagus Cancers" patented technology

A method of treating a cancer in a subject in need thereof is disclosed. The cancer can be an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma. The method comprises administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof, wherein the subject is determined to have a constitutively activating mutation of the beta-catenin protein.

The invention discloses a structural entropy guided esophageal cancer multi-modal data discriminative representation learning method, and belongs to the technical field of medical image engineering and the field of semantic understanding. The method comprises the following steps: collecting esophageal cancer multi-modal data and executing preprocessing operation; constructing a regularization framework based on the structure entropy; inputting the preprocessed esophageal cancer multi-modal number into the constructed regularization framework based on the structure entropy, and carrying out single-modal task classification clustering based on the structure entropy; and constructing an unsupervised multi-modal clustering framework guided by the structural entropy, and inputting the preprocessed esophageal cancer multi-modal number into the unsupervised multi-modal clustering framework guided by the structural entropy to perform multi-modal data clustering so as to complete esophageal cancer multi-modal data discriminative representation learning. According to the method, a structure entropy theory is introduced, a three-layer coding tree is constructed, the problem that esophagus cancer data structure information is not sufficiently utilized in a traditional method is solved, and the collapse representation problem in an unsupervised or semi-supervised scene is solved by designing different strategies for different tasks.

The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).

The ester derivatives of brefeldin A represented by Formula (I) in the inhibition of tumor proliferation. The compounds are prominent in the prevention or treatment of hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Bart's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer and colorectal cancer, and have the potential to be developed as antitumor agents.

The invention discloses an esophageal stent covering film based on bacterial cellulose and waterborne polyurethane as well as a preparation method and application of the esophageal stent covering film, and belongs to the technical field of medical stent covering films. The preparation method of the stent covering film comprises the following specific steps: preparing a SiR / PDA composite film by a dipping-oscillation method, putting the SiR / PDA composite film into an acetobacter xylinum fermentation culture solution to realize in-situ synthesis of BC on the film, mixing 5-Fu and a WPU emulsion, pouring the mixture onto the film, and drying to prepare the 5-Fu-WPU / BC / PDA / SiR esophageal stent covering film. The preparation method provided by the invention is relatively low in cost, the stent covering film based on BC and WPU prepared by the method has good swelling property, stability, thermal stability and mechanical property, and the loaded 5-Fu has stable drug release property. The esophageal stent can be effectively applied to local administration treatment of digestive tract diseases such as esophageal cancer, and a new technical scheme is provided for functional modification of a clinical esophageal stent.

The present invention relates to a method for treating tumors or inhibiting tumor proliferation, comprising administering, as a neoadjuvant therapy, a therapeutically effective amount of a programmed death-ligand 1 (PD-L1) inhibitor (for example, an anti-PD-L1 antibody) to a cancer patient in need thereof, followed by surgical resection. In particular, the present invention relates to a method for administering a PD-L1 inhibitor as a neoadjuvant therapy prior to surgery to patients with surgically resectable upper gastrointestinal cancer, for example, localized gastric cancer, esophageal cancer or liver cancer. It has been identified that the administration of a PD-L1 inhibitor, particularly an anti-PD-L1 antibody, exhibits an excellent therapeutic effect as a neoadjuvant therapy for patients with surgically resectable localized gastric cancer, esophageal cancer, and liver cancer.

The present invention belongs to the field of chemical medicine and discloses an EGFR proteolysis-targeted chimera, its preparation method, pharmaceutical composition, and application. The present invention provides an EGFR-degradable proteolysis-targeted chimera based on CP0371, a novel E3 ligase ligand with "molecular glue" functionality, and gefitinib, a target protein ligand. The EGFR proteolysis-targeted chimera prepared by the present invention can effectively induce EGFR degradation in cancer cell lines and has considerable bioavailability. It can be used to prepare EGFR inhibitors and can be used to form pharmaceutical compositions. It has a certain inhibitory effect on the proliferation of various tumor cells and is suitable for the development of cancer drugs for the treatment of colorectal cancer, lung cancer, esophageal cancer, glioblastoma, anal cancer, head and neck epithelial cancer, and other cancers.

The present invention provides a pyrazolo[1,5-a]pyrimidine-7-oxide compound, a preparation method and uses thereof, belonging to the field of chemical drugs. The structure of the pyrazolo[1,5-a]pyrimidine-7-oxide compound is shown in Formula I. Experimental results show that such compounds can effectively inhibit the growth of various tumor cells including lung cancer cells, breast cancer cells, prostate cancer cells, bladder cancer cells, and esophageal cancer cells, and have broad application prospects in the preparation of drugs for preventing and / or treating tumors.

The invention relates to the technical field of esophageal cancer early screening, in particular to an esophageal cancer early screening system and screening method using fluorescence-labeled exosome protein. Comprising the following steps: acquiring and pre-treating a patient body fluid sample to obtain a pre-treated body fluid sample; performing exosome separation on the pretreated body fluid sample to obtain an exosome suspension; carrying out specific labeling on the exosome suspension by using a fluorescent nanoprobe to obtain a fluorescently labeled exosome solution; performing fluorescence signal detection on the exosome solution subjected to fluorescence labeling, and obtaining fluorescence intensity data and multispectral fluorescence image data based on a fluorescence signal; based on the fluorescence intensity data and the multispectral fluorescence image data, in combination with clinical data of a patient, intelligent comprehensive analysis is carried out, and a screening result is obtained. The technical problems that in early screening of esophageal cancer, the screening sensitivity and accuracy are low, and data analysis is inaccurate are solved.

Provided are a combined therapy of photodynamic therapy and immunological therapy, comprising the combined administration of a porphyrin dimer salt-based photosensitizer and an immune checkpoint inhibitor, and the use thereof in treatment of recurrent and / or metastatic cancers, in particular esophageal cancer.

The present invention discloses an esophageal cancer postoperative esophageal stenosis expanded food production mold, and relates to the field of medical equipment, the esophageal cancer postoperative esophageal stenosis expanded food production mold comprises two crossed mold half bodies, the two mold half bodies are the same in structure, each mold half body comprises a clamping plate, a rotating shaft and a handle which are connected in sequence, the rotating shafts of the two mold half bodies are attached to each other, a plurality of mold pressing units used for containing food are arranged between the two clamping plates at equal intervals in the direction from the rotating shafts to the tail ends of the clamping plates, the inner diameters of the multiple mold pressing units are sequentially increased in the direction from the rotating shafts to the tail ends of the clamping plates, and each mold pressing unit comprises mold pressing grooves symmetrically formed in the inner walls of the opposite sides of the two clamping plates; according to the invention, steamed buns or breads are extruded by a mold, so that the density and hardness of food are changed, the food is more suitable for patients with esophageal stenosis to swallow, and the extruded food can absorb water to swell in the swallowing process, so that an anastomotic stoma can be expanded or expanded, and the recovery of esophageal functions of the patients is promoted.

The invention belongs to the technical field of cancer risk prediction, and particularly relates to a cancer risk prediction and evaluation system and an evaluation method, related SNP (Single Nucleotide Polymorphism) sites for cancer risk prediction comprise rs10937405, rs2131877, rs2736100, rs2853677, rs401681, rs7086803, rs748404, rs7741164, rs9387478, rs11066280, rs13042395, rs2274223, rs4072037, rs671, rs738722, rs10795668, rs3802842, rs6983267, rs7229639, the method can accurately identify specific gene variation to reduce misjudgment, has high sensitivity and specificity, and provides powerful support for early diagnosis and prevention, individualized treatment and the like of cancers.

Compositions and methods of making isolated binding molecules (e.g., antibodies) or antigen-binding fragments thereof that can be used as therapeutic agents to treat and / or prevent diseases associated with cells expressing intimate junction protein 18.2, including tumor-associated diseases, such as tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, liver cancer, head and neck cancer and gallbladder cancer. Also described are pharmaceutical formulations comprising the composition for the treatment of disease, as a single agent (e.g., a naked antibody), or as an adjuvant therapy of other antigen-binding anti-cancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 / PD-L1 monoclonal antibodies), and / or as a combination therapy, e.g., anti-CTLA-4 and anti-PD-1 / PD-L1 monoclonal antibodies). Wherein the anti-tight junction protein 18.2 antibody is administered prior to, after, or concurrently with chemotherapy.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The invention discloses a traditional Chinese medicine lozenge for treating esophageal cancer, which comprises the following medicinal materials: 40 g of borax, 10 g of agilawood, 25 g of potassium nitrate, 9 g of chlorite schist, 10 g of borneol, 9 g of sal ammoniac, 9 g of clove, 30 g of pseudo-ginseng, 1.5 g of musk and 20 g of granulated sugar, and relates to the technical field of traditional Chinese medicine lozenges. The traditional Chinese medicine composition has the effects of inhibiting cancer cell proliferation and preventing metastasis and relapse, has small burden on the body and is beneficial to disease control.

The present disclosure relates to methods for treating a tumor or inhibiting tumor proliferation comprising administering to a cancer patient in need thereof a therapeutically effective amount of a programmed death ligand 1 (PD-L1) inhibitor (e.g., an anti-PD-L1 antibody) as a neoadjuvant therapy followed by surgical resection. In particular, the present disclosure relates to methods for administering a PD-L1 inhibitor as a pre-operative therapy to a patient suffering from resectable upper gastrointestinal cancer (e.g., resectable localized gastric, esophageal or liver cancer). Administration of a PD-L1 inhibitor, in particular an anti-PD-L1 antibody, has proved to exhibit an excellent therapeutic effect as a pre-operative therapy for patients suffering from resectable localized gastric, esophageal and liver cancer.

This invention discloses an esophageal cancer lesion image assessment system, comprising a basic image processing module for generating initial lesion area focus data from input esophageal images; a doctor interaction acquisition module for collecting doctor's correction operations on the initial lesion area focus data; a preference learning module for learning individual preference parameters corresponding to the doctor based on the correction operations; and a personalized output module for calibrating the initial lesion area focus data based on the individual preference parameters and outputting personalized lesion area focus data. This esophageal cancer lesion image assessment system improves the assessment process for esophageal cancer lesions, reducing repetitive correction operations for doctors in handling consecutive cases, decreasing the additional workload as the number of cases increases, and making the initial output more aligned with the doctor's interpretation methods, thereby improving the overall efficiency of the assessment task.

The present invention provides a gene detection method and kit for detecting tumor tissue gene variation and changes before and after synchronized radiotherapy to perform therapeutic response, recurrence and survival assessment of esophageal cancer patients. The invention develops an esophageal cancer NGS analysis kit. According to 402 variation sites containing 35 genes frequently occurring in esophageal squamous epithelial cell carcinoma tissue cells, 62 specific site variation of tissues before and after esophageal squamous epithelial cell carcinoma CCRT is analyzed, and it is expected that a new prediction marker can be found. The potential markers are combined into an esophageal cancer detection kit, and the kit has extremely high value for improving the prognosis of esophageal cancer.

The invention relates to a 1H-pyrazol-[3, 4-d] pyrimidine derivative and a preparation method and application thereof, the structural formula of the 1H-pyrazol-[3, 4-d] pyrimidine derivative is as follows: R1 is selected from I, II, III or IV; r2 is selected from I or III or IV or V; r3 is selected from I or III or IV or V; r4 is selected from I; wherein I is hydrogen, straight-chain alkyl containing 1-3 carbon atoms, and isopropyl; iI is phenyl, naphthyl or substituted phenyl; iII is an unsaturated five-membered or six-membered heterocyclic group containing mono-nitrogen or multi-nitrogen; iV is an unsaturated five-membered or six-membered heterocyclic group containing single oxygen, single sulfur, nitrogen oxygen and nitrogen sulfur; and V is phenyl, naphthyl or substituted phenyl. The 1H-pyrazol-[3, 4-d] pyrimidine derivative prepared by the invention shows specific anti-proliferative activity to esophageal cancer cells, shows better in-vivo and in-vitro safety and weak cardiotoxicity, is simple in synthesis method and high in yield, and opens up a new way for researching new anti-esophageal cancer drugs.

The invention relates to an alkyl diamine substituted bis-aromatic heterocyclic thioether compound, preparation thereof and application of the alkyl diamine substituted bis-aromatic heterocyclic thioether compound in preparation of drugs for treating and / or preventing tumors. The structural formula of the alkyl diamine substituted bis-aromatic heterocyclic thioether compound is shown as (I). The alkyl diamine substituted bis-aromatic heterocyclic thioether compound has an obvious growth inhibition effect on various human tumor cells; the compound has good inhibitory activity on breast cancer, liver cancer, pancreatic cancer, kidney cancer, lung cancer, stomach cancer, glioma, ovarian cancer, prostate cancer, esophagus cancer, melanoma, nasopharynx cancer, colon cancer, cervical cancer, lymphoma, leukemia and other tumors. The IC50 effective concentration of the compound on tumor cells such as breast cancer, pancreatic cancer, lung cancer, glioma, ovarian cancer, esophagus cancer, melanoma, colon cancer and cervical cancer is lower than that of cis-platinum, and experiments show that the compound has broad-spectrum anti-tumor activity. The invention provides a new way for application of the alkyl diamine substituted bis-aromatic heterocyclic thioether compound in preparation of medicines for treating and / or preventing tumors.

To provide a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2.SOLUTION: The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head and neck cancer, and cancer of the gallbladder and metastases thereof.SELECTED DRAWING: None

A method for treating esophageal cancer in situ with heated air that can be inhaled through a face mask, at an elevated temperature less than sauna air temperatures and at a constant positive air pressure. The inhaled heated air will heat the very thin tracheoesophageal party wall sheath membrane between the esophagus and the respiratory trachea in the throat. The tracheoesophageal party wall sheath membrane therefore can heat the esophageal cancer tumor adjacent to the heated trachea and tracheoesophageal party wall sheath membrane. The heated air will be inspired / inhaled through the mouth and into the trachea / windpipe. Then the trachea and trachea tube under heated constant positive pressure will then transfer heat through and to the esophagus wall, and esophagus and tumor. The heat from the heater air inspiration through the trachea migrates / transmits / disperses across the membrane separating the trachea / windpipe from the esophagus and hits the esophagus with heat.

The invention discloses a traditional Chinese medicine preparation for treating chronic esophagitis and esophageal precancerous lesions and a preparation method thereof. The traditional Chinese medicine preparation is prepared from nux vomica, sal ammoniac, sculellaria barbata, Chinese lobelia, duchesnea indica, marsdenia tenacissima, solanum septemlobum bunge, selfheal, processed pinellia ternate, ginger, coptis chinensis, sticktight, airpotato yam, radix clematidis, borax, platycodon grandiflorum, hawthorn, kelp, seaweed, edible tulip and venenum bufonis. The preparation method comprises the following steps: processing or performing raw treatment on the materials, grinding into fine powder by using a grinder, finely screening by using a sieve, removing coarse stems, and mixing in parts by weight to obtain a finished product of the preparation. The traditional Chinese medicine is simple in preparation method and low in cost, can dissipate blood stasis, regulate liver and stomach and nourish stomach yin, and can effectively treat chronic esophagitis and esophageal precancerous lesions.

The invention relates to the technical field of nano drug loading, and provides a dual-targeting magnetic nanoparticle loaded with a traditional Chinese medicine composition, and a preparation method and application of the dual-targeting magnetic nanoparticle. The dual-targeting magnetic nanoparticle has the advantages of multiple-effect synergy, good targeting property and good biocompatibility. The nano-particle takes PLGA (poly (lactic-co-glycolic acid)) as a carrier, is loaded with an HD-PV (Hedyotis diffusa-Prunella vulgaris) ethanol extract and is coupled with magnetic CoFe2O4-SB, and the surface of the nano-particle is coated with chitosan to fix clostridium noxii spores (C.novyi-NT). The magnetic targeting and spore hypoxia targeting compound is accurately enriched in a tumor area through the synergistic effect of magnetic targeting and spore hypoxia targeting, spore germination for oncolysis is triggered under the magnetocaloric effect, meanwhile, butyrate (SB) and a traditional Chinese medicine composition are controllably released, and magnetocaloric-oncolysis-chemotherapy-traditional Chinese medicine multi-mechanism combined treatment is achieved. Experiments show that the system significantly inhibits tumor growth, is non-toxic to normal organs, has both high efficiency and safety, and provides a new strategy for accurate treatment of esophageal cancer.

The present disclosure relates to the field of therapeutic antibodies for the treatment of subjects with cancer. More specifically, the disclosure relates to the treatment of cancer using an antibody, or a functional portion, derivative, and / or analog of an antibody, comprising a variable domain that binds to the extracellular portion of EGFR, in combination therapy further comprising administration of a fluoropyrimidine, a platinum-based chemotherapeutic agent, a BCL-2 inhibitor, or SN-38. The cancer may be head and neck cancer, gastric cancer, esophageal cancer, gastroesophageal junction cancer, non-small cell lung cancer, or colorectal cancer. The disclosure also relates to pharmaceutical formulations, kit of parts and dosage regimens.

The present disclosure relates generally to compounds of Formulae (1-A), (1-B1), (1-C) and ((1-D) and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder, prostate, or ovarian cancer.

The present invention relates to a new vilazodone derivative (3-(4-(4-(2-chloro-6-methoxyphenyl)piperazine-1-yl)butyl)-cyano-indole) and a synthesis method and application thereof. The vilazodone derivative is 3-(4-(4-(2-chloro-6-methoxyphenyl)piperazine-1-yl)butyl)-cyano-indole, and its chemical structure is as follows: The compound has a significant growth inhibitory effect on a variety of human tumor cells and has excellent inhibitory activity on tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, pancreatic cancer, nasopharyngeal cancer, liver cancer, and gastric cancer. The IC50 effective concentration of the compound on tumor cells such as breast cancer, colorectal cancer, lung cancer, glioma, pancreatic cancer, and nasopharyngeal cancer is lower than that of cisplatin. Experiments show that the vilazodone derivative has a broad-spectrum anti-tumor activity and is expected to become a new anti-tumor drug.

The present invention provides a method with which it is possible to objectively and accurately assess the risk of onset of esophageal cancer, pharyngeal cancer, and / or oral cancer, non-invasively and with little burden on the subject, and an onset prediction model having high accuracy for these cancers. The purpose of the present invention is also to provide a kit that can be used in the assessment method and the onset prediction model.　The present invention is a method for predicting the onset and / or assessing the risk of esophageal cancer, pharyngeal cancer, or oral cancer in a subject, the method being characterized by comprising (A) a step for identifying a mutation in at least one gene selected from the group consisting of CHEK2, TP53, NOTCH 1, CDKN2A, NOTCH2, FAT1, PPM1D, AJUBA, ARID1A, ZFP36L2, ZNF750, and CUL3 in a nucleic acid specimen extracted from a biological sample derived from the oral mucosa of the subject and (B) a step for calculating and scoring the total (Sum of VAFs) allele frequency (VAF) and / or the total mutations (Number of mutations) of the mutation identified in step (A).

The utility model relates to the field of medical instruments, in particular to a nasal esophageal tracheal fistula three-balloon nasal feeding tube composite set loaded with radioactive particles, which comprises a tube body, a lower blocking balloon, a particle balloon, an upper blocking balloon, a tube body butt joint structure and a nasal guide structure. The radion-loaded three-balloon nasal feeding tube composite set for the nasal esophageal and tracheal fistula is a medical instrument which is combined with the nasal feeding tube and can be used for blocking and treating a fistula opening of a patient suffering from the esophageal and esophageal fistula and carrying out precise targeted radiotherapy on a cancerous part of esophageal cancer, and feeding nutrition of the patient is convenient to convey. The device is simple in structure, convenient to operate, high in working and operating efficiency, stable in operation, beneficial to popularization and promotion, capable of effectively relieving pain of patients, convenient to mount and dismount, obvious in acting effect, capable of achieving differentiated treatment, stable in whole and high in pertinence, and has wide market prospects.

The utility model provides an esophageal cancer treatment auxiliary device, which belongs to the technical field of esophageal cancer treatment, and comprises a supporting mechanism and an auxiliary mechanism, the supporting mechanism comprises a base, a stand column, a sliding piece and a supporting plate; the auxiliary mechanism comprises a connecting piece, a connecting rod and a supporting seat. The base provided with the stand column is additionally arranged and used for being matched with the sliding piece to install the auxiliary mechanism, the position of the sliding piece is adjusted along the stand column, the height of the auxiliary mechanism can be adjusted, the device can be used for butt joint of devices of different heights, the end of the sliding piece is in butt joint with the auxiliary mechanism through the supporting plate, and auxiliary mechanisms of different specifications can be conveniently installed; the supporting seat is additionally arranged to be used for fixing a pipeline of a detection instrument in a matched mode and assisting the detection instrument in examining and treating a patient, the weight of the pipeline of the instrument can be shared by the auxiliary device, pressure brought by the pipeline of the instrument to the patient is reduced, and the auxiliary mechanism and the clamping block can be conveniently disassembled, assembled and in butt joint through the plug-in type structure.